c33a human cervical cell lines  (Procell Inc)

Journal: Cell Death & Disease

Article Title: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates

doi: 10.1038/s41419-024-07073-y

Figure Lengend Snippet: A The expression of ZDHHC3 protein in cancers based on the Human Protein Atlas: ZDHHC3 expression levels are evaluated according to the immunohistochemistry staining on cancer tissue samples of the Human Protein Atlas database. The X axis represents the cancer type. Pan-cancer includes 20 different cancer types. BRCA, breast cancer. CESC, cervical cancer. SKCM, skin cancer and melanoma. HNSC, head and neck cancer. The Y axis represents the percentage of patients with specific expression pattern of ZDHHC3. High, high expression. Low, low expression. None, no expression. B The correlation between PDL1 (CD274) and PD1(PDCD1), ZDHHC1, ZDHHC2, or ZDHHC3 expression in TCGA cancer types. TIMER2.0 Gene_Corr Module is used to evaluate the expression between two genes in different cancer types of TCGA database. The heatmap lists the purity-adjusted partial spearman’s rho (Cor) value as the degree of the correlation between two genes and the number (n) of patient cases in each cancer typer. C Western blot analysis was utilized to examine the expression of PD-L1 protein in MDA-MB-231 and C33A cells following the knockdown of DHHC1, DHHC2, and DHHC3. D A schematic representation of the structural design of cp-PCC. E Western blot analysis was conducted to assess the expression of PD-L1 protein in four cell lines (MDA-MB-231, C33A, FaDu, A375) following a 6-hour incubation with 10 µM PCC16/17/18, each corresponding to CRBN/VHL/IAP-based cp-PCC, respectively. Quantitative data are presented as mean ± standard error. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test ( n = 3): * P < 0.05, ** P < 0.01, ***P < 0.001.

Article Snippet: Human cervical cancer cell line C33A, mouse mammary carcinoma cell line 4T1, and mouse cervical cancer cell line U14 were purchased from ATCC.

Techniques: Expressing, Immunohistochemistry, Staining, Western Blot, Knockdown, Incubation

Journal: Cell Death & Disease

Article Title: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates

doi: 10.1038/s41419-024-07073-y

Figure Lengend Snippet: A – C Western blot analysis was utilized to examine the expression of DHHC3/PD-L1 proteins in C33A cells following 6 h of treatment with varying concentrations of PCC16/17/18. D Comparative analysis of the DC50 values for PCC16/17/18. E – G Western blot analysis to assess the expression of DHHC3/PD-L1 proteins in C33A cells post-incubation with specific concentrations of PCC16/17/18 for different time periods. H Confocal microscopy was employed to observe the fluorescence intensity of PCC16/17/18 entering the cells at various time points. Quantitative data are presented as mean ± standard error. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test ( n = 3): * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: Human cervical cancer cell line C33A, mouse mammary carcinoma cell line 4T1, and mouse cervical cancer cell line U14 were purchased from ATCC.

Techniques: Western Blot, Expressing, Incubation, Confocal Microscopy, Fluorescence

Journal: Cell Death & Disease

Article Title: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates

doi: 10.1038/s41419-024-07073-y

Figure Lengend Snippet: A Confocal observation of DHHC3 binding with drug PCC16. Scale bar, 1 µM. B C33A cell lysates treated at different temperatures after incubation with 0.5 µM PCC16, with Western blot analysis of DHHC3 protein expression; C CETSA melting curve plotted. D Flow cytometry analysis of fluorescent cells after treatment with Rhodamine-labeled PCC16 at different concentration gradients; E C33A cells treated with PCC16 over time and concentration gradients, with cell toxicity of PCC16 measured by MTT assay.

Article Snippet: Human cervical cancer cell line C33A, mouse mammary carcinoma cell line 4T1, and mouse cervical cancer cell line U14 were purchased from ATCC.

Techniques: Binding Assay, Incubation, Western Blot, Expressing, Flow Cytometry, Labeling, Concentration Assay, MTT Assay

Journal: Cell Death & Disease

Article Title: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates

doi: 10.1038/s41419-024-07073-y

Figure Lengend Snippet: A C33A cells pre-treated with/without MG132 for 4 h and then treated with PCC16/17/18, with Western blot analysis to detect PD-L1 protein levels; B Bar graph representing the quantification of grayscale values; C Confocal microscopy observation of the immunofluorescence intensity of PD-L1 protein under PCC16/17/18 ± MG132 conditions. Scale bar, 10 μM. Quantitative data expressed as mean ± standard error; analyzed by one-way ANOVA with Tukey’s post hoc test ( n = 3): * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: Human cervical cancer cell line C33A, mouse mammary carcinoma cell line 4T1, and mouse cervical cancer cell line U14 were purchased from ATCC.

Techniques: Western Blot, Confocal Microscopy, Immunofluorescence

Journal: Cell Death & Disease

Article Title: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates

doi: 10.1038/s41419-024-07073-y

Figure Lengend Snippet: A Western blot analysis of the effects of PCC series drugs and PD-L1 monoclonal antibody on PD-L1 protein levels in C33A cells; B TUNEL assay to assess apoptosis in cervical cancer cells treated with cisplatin and PCC16; C Ki67 assay for evaluating the proliferation of cervical cancer cells treated with cisplatin and PCC16; D Plate cloning experiment analyzing the proliferation of cervical cancer cells treated with cisplatin and PCC16; E In a C33A-T cell co-culture model, ELISA was used to measure IFN-γ and TNF-α expression levels after treatment with different concentrations of PCC16; F Hoechest33528 staining in the co-culture system to observe apoptosis of C33A cells after treatment with different concentrations of PCC16. Quantitative data are expressed as mean ± standard error; analyzed by one-way ANOVA with Tukey’s post hoc test ( n = 3): * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: Human cervical cancer cell line C33A, mouse mammary carcinoma cell line 4T1, and mouse cervical cancer cell line U14 were purchased from ATCC.

Techniques: Western Blot, TUNEL Assay, Cloning, Co-Culture Assay, Enzyme-linked Immunosorbent Assay, Expressing, Staining

Journal: Biomolecules and Biomedicine

Article Title: Role of Fascin-1 in cervical cancer metastasis via Wnt/β-catenin pathway activation

doi: 10.17305/bb.2025.12114

Figure Lengend Snippet: Impact of Fascin-1 on in vitro growth of cervical cancer cells. (A) Assessment of Fascin-1 levels in Hela and C33A cells through Western blot, post-infection with lentiviruses carrying either FSCN1 -targeting shRNAs or control shRNAs; (B) RT-PCR analysis of FSCN1 mRNA levels when knockdown FASCIN; (C) Evaluation of cell proliferation in Hela and C33A cells with FSCN1 or control shRNA expression, using MTT assays; (D) Growth of Hela and C33A cells expressing respective shRNAs, cultured for 10 days and stained with crystal violet; colony counts were recorded; (E) Western blot analysis of cell lysates from Hela and C33A cells stably expressing FLAG- FSCN1 empty vector; (F) RT-PCR analysis of FSCN1 mRNA levels when overexpressed FSCN1 ; (G) Proliferation analysis via MTT assays in cells with either control or FSCN1 overexpression; (H) Analysis of colony formation in cells with indicated treatments; (I) Cell cycle experiments in indicated cells. Data for – and – are presented as mean ± SD, n ═ 3; *** P < 0.001, ** P < 0.01, * P < 0.05 (Student’s t -test). shRNA: Short hairpin RNA.

Article Snippet: The Hela and C33A human cervical cell lines were purchased from Procell Life Science & Technology Co., Ltd. (Wuhan, China) and cultured in RPMI 1640 and MEM media, respectively, both supplied by Meilunbio (Dalian, China).

Techniques: In Vitro, Western Blot, Infection, Control, Reverse Transcription Polymerase Chain Reaction, Knockdown, shRNA, Expressing, Cell Culture, Staining, Stable Transfection, Plasmid Preparation, Over Expression

Journal: Biomolecules and Biomedicine

Article Title: Role of Fascin-1 in cervical cancer metastasis via Wnt/β-catenin pathway activation

doi: 10.17305/bb.2025.12114

Figure Lengend Snippet: Enhancement of cervical cell migration by Fascin-1 in vitro . (A and B) Migration and invasion capacities of Hela and C33A cells, with either FSCN1 shRNAs or control shRNAs, were assessed through respective assays; (C and D) Cells overexpressing either empty vectors or FLAG-tagged FSCN1 were analyzed for migration and invasion abilities. Scale bars represent 100 µm. Statistical data are presented as mean ± SD ( n ═ 3); *** P < 0.001, ** P < 0.01, * P < 0.05 (Student’s t -test).

Article Snippet: The Hela and C33A human cervical cell lines were purchased from Procell Life Science & Technology Co., Ltd. (Wuhan, China) and cultured in RPMI 1640 and MEM media, respectively, both supplied by Meilunbio (Dalian, China).

Techniques: Migration, In Vitro, Control

Journal: Biomolecules and Biomedicine

Article Title: Role of Fascin-1 in cervical cancer metastasis via Wnt/β-catenin pathway activation

doi: 10.17305/bb.2025.12114

Figure Lengend Snippet: Downregulation of Fascin-1 impairs Wnt/β-catenin signaling. (A) GSEA enrichment plot of Wnt signaling pathway using RNA-seq data generated from Hela cells; (B) Heatmap of genes involved in Wnt signaling pathway; (C) mRNA was isolated from Hela and C33A cells expressing specific shRNAs, and quantitative real-time RT-PCR assays were conducted to measure expression levels; (D) RT-PCR analysis of FSCN1 , CTNNB1 and c-Myc mRNA levels in the indicated cells; (E and F) Protein lysates from indicated Hela and C33A cells, were analyzed by Western blot using relevant antibodies; (G) pTop-Flash/pFop-Flash reporter vectors were used to evaluate the transcriptional activity of the Wnt/β-catenin signaling pathway. Each bar in the graph indicates the average ± SD from three independent experiments, *** P < 0.001 compared to control (Student’s t -test). GSEA: Gene set enrichment analysis.

Article Snippet: The Hela and C33A human cervical cell lines were purchased from Procell Life Science & Technology Co., Ltd. (Wuhan, China) and cultured in RPMI 1640 and MEM media, respectively, both supplied by Meilunbio (Dalian, China).

Techniques: RNA Sequencing, Generated, Isolation, Expressing, Quantitative RT-PCR, Reverse Transcription Polymerase Chain Reaction, Western Blot, Activity Assay, Control